| Description | Lersivirine (UK-453061)(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy. |
| Target activity | NNRT:119 nM (IC50) |
| Synonyms | 3-氰基-5-[[3,5-二乙基-1-(2-羟基乙基)-1H-吡唑-4-基]氧基]苯腈, Lersivirine(UK 453061), UK-453061 |
| molecular weight | 310.35 |
| Molecular formula | C17H18N4O2 |
| CAS | 473921-12-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (161.11 mM), Sonication is recommended. |
| References | 1. Davis J, et al. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur J Clin Pharmacol. 2012 Nov;68(11):1567-72. 2. Mowbray CE, et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5857-60. |